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In this issue of the JCI, Wang, Clemens, and colleagues demonstrate that
hypoxia-inducible factor α (HIFα) signaling in bone-building osteoblasts is
central to the coupling of angiogenesis and long bone development in mice
(see the related article beginning on page 1616). They show that bone formation controlled by osteoblast HIFα signaling is not cell autonomous but
is coupled to skeletal angiogenesis dependent upon VEGF signaling. Thus,
strategies that promote HIFα signaling in osteoblasts may augment bone
formation and accelerate fracture repair.
Tremendous unmet clinical needs exist in
musculoskeletal medicine. The direct costs
of musculoskeletal diseases in the Unites
States are well over $100 billion per annum
(1). Osteoporosis and osteoarthritis are recognized as common and clinically important, but other serious skeletal diseases also
afflict our populace. In the setting of type 2
diabetes mellitus (T2DM), lower-extremity
musculoskeletal disease is prevalent, costly,
and exceedingly difficult to manage, with
fracture, arthropathy, ischemia, ulcer, and
infection commonly confronting patients
and clinicians. The total costs associated with lower-extremity amputation in
T2DM alone are greater than the combined
costs of treating fatal and nonfatal myocardial infarction associated with T2DM
(2). Stage-specific and disease-specific
strategies are necessary to safely promote
bone formation in individuals with: (a)
underlying vasculopathies, such as those
associated with diabetes or renal failure;
(b) underlying malignancy of any sort; (c)
extant osteoporosis that has removed trabecular templates for bone apposition; (d)
Nonstandard abbreviations used: BMP, bone morphogenetic protein; BV/TV, bone volume/tissue volume; HIF, hypoxia-inducible factor; ΔHif1a mice, mice
with conditional deletion of Hif1a in osteoblasts; PHD,
prolyl hydroxylase; pVHL, von Hippel–Lindau protein;
SM22, smooth muscle 22 kDa; T2DM, type 2 diabetes
mellitus; TNFR2, TNF receptor 2; ΔVhl mice, mice with
conditional deletion of Vhl in osteoblasts; ΔVhl/ΔHif1a
mice, mice with conditional deletion of both Vhl and
Hif1a in osteoblasts.
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osteoporosis in the setting of childhood
growth and open epiphyses; and (e) drugor coagulopathy-related disorders that
cause avascular necrosis.
In this issue of the JCI, the study by Wang
et al. (3) affords us a better understanding
of the mechanisms coupling bone and vascular physiology, providing insights useful for devising novel strategies to address
the mounting unmet needs in orthopedic medicine. The vasculature provides:
(a) a sustentacular niche and source of
adult mesenchymal stem cells, including
osteoprogenitors; (b) the organizational
and rate-limiting “point of reference” for
Haversian bone formation; and (c) the
conduit for calcium, phosphate, hematopoietic, and nutrient supply necessary for
mineralization and calcium mobilization
(4–11). We know precious little about how
the vasculature integrates and conveys signals during skeletogenesis. However, VEGF
(9) has emerged as the prototypic osteogenic-angiogenic coupling factor (10). The
VEGF gene encodes a secreted polypeptide
globally required for vasculogenesis and
angiogenesis (11). Bioactivity is modulated
by VEGF gene expression — and differential splicing that generates three unique
gene products — with signals transduced
via specific VEGF receptor tyrosine kinases
(9). The name “VEGF” belies its contributions to osteoblast ontogeny, chondrocyte
physiology, and osteoclast formation (10).
VEGF signaling is tightly regulated in bone,
coupled to morphogenetic, metabolic,
inflammatory, and mechanical cues that
control mineral metabolism. In addition
to regulating the expansion and survival
of mesenchymal progenitors (Figure 1 and
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below), signals provided by VEGFR2 mediate angiogenic cross-talk with TNF receptor 2 (TNFR2) (12), critical for postnatal
defense against limb ischemia (13). Given
the contributions of bone-vascular interactions to all aspects of bone biology, our
limited understanding of this important
physiology impedes development of novel
bone anabolic therapies.
/FXIJOUTGSPN)*'
In their current study, Wang, Clemens, and
colleagues (3) significantly advance our
understanding of bone-vascular coupling
by establishing the critical role for osteoblast hypoxia-inducible factor 1α (HIF-1α)
and HIF-2α in bone formation (Figure 1).
As recently reviewed (14), HIFs are components of heterodimeric, hypoxia-activated transcription factor complexes that
bind to well-characterized DNA cognates
called hypoxia-response elements, activating the expression of genes such as VEGF
and erythropoietin that can improve tissue
oxygen delivery (15). Dependent upon cellular context, HIF-1α and HIF-2α may or
may not exhibit functional redundancy
(14). The Clemens group first showed that
osteoblasts express all necessary components of the oxygen-sensing pathway in
addition to HIF-1α and HIF-2α (herein
collectively referred to as HIFα). These
components include the oxygen-dependent prolyl hydroxylases (PHDs) that “tag”
HIFα for recognition by the E3 ubiquitin
ligase von Hippel–Lindau protein (pVHL)
and pVHL itself, necessary for HIFα proteosomal degradation (3) (Figure 1). Moreover, the authors demonstrate hypoxiadependent nuclear accumulation of HIFα
and concomitant upregulation of VEGF
expression, indicating intact oxygen-sensing functions in osteoblasts. To evaluate
the biological importance of osteoblast
HIF signaling in vivo, the authors used
Cre-lox technology; they implemented the
bone-specific human osteocalcin promoter
as a delivery module for Cre recombinase
expression in mice possessing floxed Vhl
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alleles. This strategy abrogates pVHL accumulation in mature osteoblasts (3). In this
conditional knockout, denoted ΔVhl, osteoblast accumulation of both HIF-1α and
HIF-2α was induced due to the absence
of pVHL-dependent degradation (Figure
1). The in vivo effects on long bone formation were remarkable; bone volume/tissue
volume (BV/TV) increased by 70% with
osteoblast-specific induction of HIFα subunits. Detailed histomorphometry revealed
very early postnatal increases in trabecular
osteoblast numbers during long bone modeling — numbers that “normalized” once
a new steady state of high bone mass was
achieved in ΔVhl mice (3). In culture, osteoblasts possessing floxed Vhl alleles also
upregulated HIFα when transduced with
an adenoviral Cre vector — with concomitant induction of VEGF. HIFα induction


did not alter cultured osteoblast proliferation rate, apoptotic rate, matrix synthetic
activity, or mineral deposition ex vivo; thus,
the bone anabolic actions of osteoblast
HIFα induction observed in vivo were not
cell autonomous. Bone histomorphometry and serum biochemistries showed no
decrements in bone-resorbing osteoclast
numbers or activity, excluding overt contributions of osteoclast insufficiency to
increased BV/TV in ΔVhl mice. However, a
profound increase in bone vascularity was
observed for the ΔVhl mice (3). Moreover, a
massive increase in capillary sprouting was
exhibited by ΔVhl long bones maintained
in organ culture (3). Angiogenic responses
were dependent upon paracrine VEGF
actions, since: (a) VEGF-neutralizing antibody abrogated sprouting; and (b) skeletal
production of VEGF mRNA was increased
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in ΔVhl mice without changes in circulating
VEGF. Relationships to HIFα-dependent
angiogenesis and bone formation were further confirmed using mice in which Hif1a
was conditionally knocked out in osteoblasts (ΔHif1a mice). Bone volume and vascularity were reduced in ΔHif1a mice, with
reductions partially offset by compensatory
HIF-2α expression. The overlapping redundancy of the latter was diligently demonstrated using a third mouse model, Vhl gene
deletion in ΔHif1a mice; these ΔVhl/ΔHif1a
mice exhibited markedly increased HIF-2α
protein accumulation, with concomitant
restoration of bone volume and angiogenesis (3). Thus, the authors conclude
that osteoblast HIFα signaling is a central
component of rate-limiting, osteogenicangiogenic coupling that controls long
bone formation. This coupling occurs via
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mechanisms that are not cell autonomous
and that utilize paracrine VEGF angiogenic
signals to expand osteoblast numbers during long bone development (3).
"OHJPHFOFTJTBOEPTUFPCMBTU
POUPHFOZ
How, then, might the angiogenic response
and osteogenic-angiogenic coupling
increase osteoblast numbers and provide the massive marrow bone formation
observed (3)? Recently, several groups have
identified the microvascular smooth muscle cell, the pericyte, as an important osteoprogenitor (16–24) (Figure 1). Demer, Canfield, and colleagues have shown that the
pericyte exhibits multipotentiality, capable
of osteogenic, chondrogenic, adipogenic,
and SMC differentiation (17, 18). Molecularly, pericytes express early features of the
VSMC lineage, including smooth muscle
22 kDa (SM22), α-SMC, and species-specific gangliosides demarcated by the 3G5
monoclonal antibody (17, 19). Anatomically, the pericyte is intimately juxtaposed
to the endothelial capillary network. In the
marrow microenvironment, the bone marrow stromal cell exhibits the histoanatomic
characteristics of the pericyte (16). Thus,
from this perspective the bone marrow
stromal cell — the osteoprogenitor — can
be viewed as a tissue-specific pericyte.
What is the ontogeny of the vascular
pericyte? Cossu and colleagues provide
data suggesting that the mesoangioblast
(20), a vessel-associated mesenchymal
stem cell with the capacity to differentiate into cells of endothelial and VSMC
lineages, might be the source of pericytes.
Studies of differentiating murine ES cells
confirm the existence of a highly plastic,
VEGFR2+ endothelial-SMC progenitor —
a mesenchymal stem cell that can give rise
to mineralizing osteoblasts in culture via
pericytic SMC lineage (23). Skeletal osteoblasts can and do arise from the pericyte
cell lineage in vivo; SM22-positive and
α-SMC–positive cells “coregister” with
preosteoblasts identified using Col3.6GFP reporter mice following induction
of de novo osteogenesis (24). Thus, concomitant with angiogenic sprouting,
VEGF/VEGFR2 signaling is posited to
expand the potential osteoprogenitor
pool via the pericyte intermediate (Figure
1). However, until better pericyte lineage
markers are developed, or the effects of
HIFα expansion are tested in the lineage
reporter mice (24), the mechanisms proposed remain speculative.

-PDBUJPO MPDBUJPO MPDBUJPO
Remarkably, unlike in long bone, little if
any in vivo effect of osteoblast Vhl deletion
was observed by Wang et al. in calvarial
bone (3). Why might this occur? Unique
and differentially regulated ontogeny and
angiogenic responses likely contribute (25).
There are places in the skeleton (e.g., neural
crest–derived calvarial bone, lateral components of the clavicle, the mid-diaphyseal
collar of long bone) where bone forms via
nonendochondral mechanisms (11, 25).
Denoted as intramembranous ossification, this osteoblast-mediated mineral
deposition occurs directly in the type I collagen–based extracellular matrix — without
replacement of a precedent, avascular cartilaginous template by bone and marrow as
is required for endochondral ossification
(10, 25). In the developing skull, it is probable that cranial suture and dural mechanical tension organize angiogenesis necessary
for intramembranous ossification (26–28).
VEGF expression in osteoblasts is mechanically very responsive (29). Distraction
osteogenesis — an orthopedic mechanical
manipulation that promotes robust angiogenesis and bone formation via nonendochondral mechanisms — upregulates both
HIF-1α and VEGF (29). Thus, it is tempting
to speculate that the differences observed
by Wang et al. (3) arise due to differences
in the rate-limiting stimuli that control
osteogenic-angiogenic coupling in calvarial versus long bone development. For the
moment, however, the precise reasons for
the differences observed between long bone
and calvarial bone formation following Vhl
deletion remain to be determined.
'VUVSFEJSFDUJPOT
Many questions remain to be answered.
Although HIFα clearly regulates osteogenic-angiogenic interactions necessary for
bone formation, other secreted molecules
in addition to VEGF, such TNF-α (6, 12,
13) and FGF2 (5, 27, 28), might contribute
to this coupling. Potential contributions of
paracrine TNF-α signaling — an important
activator of TNFR2-VEGFR2 cross-talk
(12, 13) and bone formation (6) — have yet
to be detailed. Should administration of
bevacizumab, a clinically useful inhibitory
antibody to VEGF (30), be shown to abrogate the bone anabolic effects of osteoblast
HIFα, this would provide pharmacologic
evidence that paracrine VEGF signals are
nonredundant in osteogenic-angiogenic
coupling. Moreover, since VEGF induces
the production of bone morphogenetic pro-
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tein (BMP) by endothelial cells (5), the consequences of inactivating endothelial BMP
expression would help support the evolving
working model (Figure 1). The mechanisms
that punctuate feed-forward osteogenicangiogenic coupling are not known but
clearly exist, since osteoblast numbers and
bone formation quickly normalizes postnatally at a higher bone mass (3). The “osteostat” mechanism responsible for this physiologic response will be extremely important
to delineate — and may be metabolically as
well as mechanically determined. It may
be possible to selectively augment skeletal
HIF-1α action — potentially by inhibiting
specific PHDs — as one strategy to promote bone formation and fracture healing.
It will be important to evaluate how the
material and geometric properties of bone
manipulated via the HIFα pathway impact
bone strength. Finally, better markers are
required to unambiguously characterize
precursor-product relationships in the
mesoangioblast/pericyte/osteoblast lineage; such ontogeny is likely to contribute
to changes in trabecular bone mass dependent upon osteoblast HIFα signaling (16,
18). All in all, novel and very important biological principles emerge from the current
study (3), i.e., that osteogenesis and angiogenesis are functionally coupled in the marrow microenvironment by osteoblast HIFα
signaling. Thus, in addition to osteoblast
and osteoclast lineages, the contributions
of endothelial cell precursors and their
progeny (Figure 1) must be considered in
robust studies of bone formation and skeletal homeostasis.
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A new study by Galeano and colleagues in this issue of the JCI reports the
first glomerular disease caused by a genetic defect in sialic acid biosynthesis (see the related article beginning on page 1585). Mice that harbor mutations in the Gne/Mnk gene produce lower amounts of sialic acid, suffer
from hematuria, proteinuria, and structural defects in the glomerulus and
die within days after birth. Remarkably, the lesion can be reversed through
dietary addition of N-acetylmannosamine, a sialic acid precursor, raising the
intriguing possibility that this approach might have therapeutic benefit in
patients with glomerular disease.
In this issue of the JCI, Galeano, Huizing,
and colleagues (1) describe kidney defects in
knockin mice that harbor the M712T mutaNonstandard abbreviations used: Gne, uridine
diphospho–N-acetylglucosamine 2-epimerase; HIBM,
hereditary inclusion body myopathy; ManNAc, N-acetylmannosamine; Mnk, ManNAc kinase; PC, podocalyxin; SD, slit diaphragm.
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tion in the gene encoding the key bifunctional enzyme of sialic acid biosynthesis — uridine
diphospho–N-acetylglucosamine 2-epimerase/N-acetylmannosamine (ManNAc)
kinase (GNE/MNK) (GneM712T/M712T mice)
(2, 3). In patients, mutations in the GNE
gene result in the autosomal recessive neuromuscular disorder, hereditary inclusion
body myopathy (HIBM; MIM 600737) that
presents late in life as a slowly progressive
myopathy (4, 5). The N-acetylglucosamine/
ManNAc enzyme is ubiquitously expressed
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and catalyzes the first rate-limiting steps
in the biosynthesis of sialic acid (Figure 1).
5-N-acetylneuraminic acid (Neu5Ac) is the
most plentiful mammalian sialic acid and
is the terminal sugar on glycoconjugates,
where it functions in cellular interactions
and signaling. Muscle fibers from patients
with HIBM exhibit reduced sialylation of
proteins, which is believed to underlie disease
pathogenesis. Currently, there is no effective
therapy for this disorder.
In the current study (1), the investigators sought to develop a mouse model to
test whether dietary supplementation of
sialic acid or its precursor, ManNAc, could
reverse the hyposialylation defect observed
in patients. Standard Gne knockout mice
die in utero (6). To overcome this early
mortality, the authors generated a mouse
carrying one of the most common nonlethal mutations observed in patients with
HIBM. Surprisingly, mice homozygous for
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